Taipei, Taiwan, 13th September 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at.
Taipei, Taiwan, 8th December 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes ve.
Taipei, Taiwan, 1st December 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E fundin.
BRIM Biotechnology enters OTC trading in TaiwanTaipei, Taiwan, 23rd June 2022 / Sciad Newswire / BRIM Biotechnology, Inc. (BRIM, TWSE 6995) enters OTC trading in Taiwan on 23rd June 2022, CST. The news was announced at the company’s first earnings call on 22nd June 2022..
Taipei, Taiwan, 23rd June 2022 / Sciad Newswire / BRIM Biotechnology, Inc. (BRIM, TWSE 6995) enters OTC trading in Taiwan on 23rd June 2022, CST. The news was announced at the company’s first earnings call on 22nd June 2022.Established in July 2013, BRIM is a clinical-stage company developing novel regenerative ther.